A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

  • End date
    Feb 15, 2024
  • participants needed
  • sponsor
    Sumitomo Dainippon Pharma Oncology, Inc
Updated on 15 September 2021
metastatic melanoma
granulocyte colony stimulating factor
systemic therapy
serum pregnancy test
measurable disease
squamous cell carcinoma
gilbert's syndrome
international normalized ratio
colony stimulating factor
neutrophil count
liver metastasis
pet scan
blood transfusion
adjuvant therapy
primary cancer
cancer chemotherapy
solid tumour
ovarian cancer
solid neoplasm
fallopian tube
metastatic gastric cancer
metastatic urothelial carcinoma
health screening
metastatic cervical cancer
metastatic renal cell carcinoma
platinum doublet
formalin-fixed paraffin-embedded
peritoneal cancer
primary peritoneal carcinoma
cancer of the ovary
immunologic adjuvant
gastroesophageal junction adenocarcinoma


This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search part of the study (Phase 1b and Phase 1b Enrichment Cohort) and the dose expansion part of the study (Phase 2). In Phase 1b of this study there will be 2 arms: Arm 1 and Arm 2. In Arm 1, there will be 6 to 12 patients who will be dosed with DSP-7888 Dosing Emulsion and nivolumab and in Arm 2 there will be 6 to 12 patients who will be dosed with DSP-7888 Dosing Emulsion and pembrolizumab. In addition, an enrichment cohort of a further 10 patients who have locally advanced or metastatic Renal Cell Carcinoma or Urothelial Cancer with primary or acquired resistance to previous checkpoint inhibitors will be enrolled into Phase 1b of the study to help evaluate the preliminary antitumor activity of DSP-7888 Dosing Emulsion at the safe dose level identified in the dose-search part of the study, and will be dosed with DSP-7888 Dosing Emulsion and nivolumab, or DSP-7888 Dosing Emulsion and pembrolizumab, as per the investigator's preference. At the safe, recommended dose determined in Phase 1b, platinum-resistant ovarian cancer (PROC) patients will be enrolled in Phase 2 of the study with DSP-7888 Dosing Emulsion, exploring the combination with pembrolizumab (Arm 2). In Phase 2, approximately 40 patients with PROC will be initially enrolled; additional patients may be enrolled to further assess anti-tumor activities, but the total sample size will not exceed 60 patients. This brings the total maximum study population to approximately 84 patients.

Condition Non-Small Cell Lung Cancer, Cervical Cancer, Adenocarcinoma, Colorectal Cancer, Disorders of cervix NOS, Malignant neoplasm of kidney, Rectal disorder, Uterine Cancer, Cancer, Fallopian Tube Cancer, melanoma, Transitional cell carcinoma, Renal Cell Carcinoma, skin cancer, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Gastropathy, Gastric Cancer, Stomach Discomfort, Metastatic Melanoma, Colon Cancer Screening, Cancer/Tumors, Rectal Disorders, Colon cancer; rectal cancer, Primary Peritoneal Cancer, Squamous Cell Carcinoma of the Head and Neck, Head and Neck Squamous Cell Carcinoma, Ewing's Family Tumors, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of Head and Neck, Gastric Carcinoma, Cancer (Pediatric), Urothelial Neoplasm, Platinum Resistant Ovarian Cancer, Kidney Cancer, Malignant Melanoma, Liver Cancer, Malignant Adenoma, Stomach Cancer, Neoplasms, Renal Cell Cancer, Renal Cancer, Urothelial Carcinoma, Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR), Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR), Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR), Serous Epithelial Ovarian Cancer, Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR), cervical carcinoma, clear cell renal cell carcinoma, colorectal neoplasm, gastric cancers, colorectal cancers, nsclc, fallopian tube cancers, cervical cancer, uterine, carcinoma of the cervix uteri, carcinoma of the cervix, cervix cancer, cancer of the cervix, carcinoma of cervix, liver cell carcinoma, cancer, colorectal, colorectal tumor, tumors, colorectal, Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR), Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR), Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR)
Treatment Pembrolizumab, Nivolumab, Atezolizumab, DSP-7888 Dosing Emulsion
Clinical Study IdentifierNCT03311334
SponsorSumitomo Dainippon Pharma Oncology, Inc
Last Modified on15 September 2021


How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note